Related Experiment Videos
Adjuvant endocrine therapy
1Karolinska Institute and Huddinge University Hospital, Södersjukhuset, SE-181 86 Stockholm, Sweden. lars-erik.rutqvist@hs.se
Best Practice & Research. Clinical Endocrinology & Metabolism
|December 23, 2003
Summary
Adjuvant endocrine therapy is the standard treatment for most invasive breast cancers. This review covers ovarian ablation, aromatase inhibitors, tamoxifen duration, biomarkers, and future directions in hormonal therapy.
Area of Science:
- Oncology
- Endocrinology
- Clinical Trials
Background:
- Endocrine therapy has been a foundational treatment for breast cancer for over 100 years.
- Numerous randomized trials over the past 30 years have refined its use in the adjuvant setting.
Purpose of the Study:
- To provide a comprehensive overview of the current state of adjuvant endocrine therapy for invasive breast cancer.
- To focus on key issues including ovarian suppression, aromatase inhibitors, tamoxifen, biomarkers, and combination therapies.
Main Methods:
- Review of extensive randomized clinical trial data involving tens of thousands of patients.
- Synthesis of evidence regarding various endocrine agents and treatment strategies.
Main Results:
- Hormonal therapy is established as the standard adjuvant systemic treatment for the majority of invasive breast cancer patients.
- Evidence supports the use of ovarian ablation/LHRH analogues in pre-menopausal women and third-generation aromatase inhibitors.
Conclusions:
- Adjuvant endocrine therapy is crucial for most invasive breast cancers, regardless of patient age, menopausal status, or tumor stage.
- Ongoing research focuses on optimizing duration, predictive biomarkers, managing side effects, and exploring combination therapies for improved outcomes.